Idursulfase 6 mg/3 mL, Concentrate for Solution for Infusion
Consumer Medicine Information
What is in this leaflet
This leaflet answers some common questions about Elaprase.
It does not contain all the available information about Elaprase.
It does not take the place of talking to your doctor or a trained health care professional.
All medicines have risks and benefits. Your doctor has weighed the risks of you or your child having Elaprase against the
benefits they expect it will have.
If you have any concerns about this medicine, ask your doctor or nurse.
Keep this leaflet.
You may need to read it again.
What Elaprase is used for
Elaprase is used as enzyme replacement therapy to treat Hunter syndrome (Mucopolysaccharidosis II), a rare genetic disease
in which an enzyme called iduronate-2-sulfatase is missing or the level of the enzyme is lower than normal.
Hunter syndrome generally occurs in males and rarely in females.
Elaprase is available only with a doctor's prescription. Only your or your child’s treating doctor can start the treatment
and supervise the ongoing treatment.
Elaprase is to be given only to the person for whom it has been prescribed.
How it works
Patients with Hunter syndrome do not produce enough of their own enzyme, iduronate-2-sulfatase. The reduced iduronate-2-sulfatase
levels in patients result in the accumulation of substances called glycosaminoglycans (GAG) in a number of cells and tissues.
This causes the affected cells and tissues to function abnormally, thereby causing problems for various organs in the body.
Elaprase is an enzyme replacement therapy that is intended to restore sufficient levels of enzyme to assist in the removal
of the accumulated substances and to reduce further accumulation.
Ask your treating doctor if you have any questions about why it has been prescribed for you or your child.
Before you are given Elaprase
When you or your child must not be given it
Do not take Elaprase if you or your child have a known, severe, life-threatening allergic reaction to:
any of the ingredients listed at the end of this leaflet
Symptoms of an allergic reaction may include:
shortness of breath
faintness or dizziness
skin rash, itching or hives
If you are not sure whether you or your child should have Elaprase, talk to your doctor or nurse.
Before you or your child are given it
Tell your doctor if you or your child have had reactions to any previous treatments, including any of the following reactions:
Tell your doctor if you or your child have allergies to:
any other medicines
any other substances, such as foods, preservatives or dyes
Tell your doctor if you or your child is suffering from any of the following:
Flu-like symptoms and fever
Tell your doctor if you are pregnant or intend to become pregnant.
There is no information available regarding the use of Elaprase in pregnant women.
Your doctor will discuss the possible risks and benefits of having Elaprase during pregnancy.
Tell your doctor if you are breast-feeding.
It is not known whether Elaprase passes into breast milk. If there is a need to consider using Elaprase while you are breastfeeding,
your doctor will discuss with you the benefits and risks of using it.
Tell your doctor if your child is under 16 months of age and has been prescribed Elaprase.
Safety in children below the age of 16 months has not been studied. If your child has been prescribed Elaprase, you may wish
to discuss this with your child’s doctor.
Taking other medicines
Tell your doctor or nurse if you or your child are taking any other medicines, including any that you buy without a prescription
from your pharmacy, supermarket or health food shop.
It is not known whether there are interactions between Elaprase and other medicines.
Your doctor or nurse will advise you and decide whether or not to give you or your child Elaprase.
How Elaprase is given
How much to use
The recommended dosage for Elaprase is 0.5 mg (half a milligram) for every kg you weigh, once every week.
Your doctor will decide on the dose that is most suitable.
How to use it
Elaprase will be prepared and given to you or your child by a trained health care professional who is knowledgeable in the
treatment of Hunter syndrome or other inherited metabolic disorders.
Treatment with Elaprase may be given in the clinic or in certain cases, at home.
Treatment at home must be administered by a healthcare professional. Your doctor will determine if home treatment is appropriate
for you or your child.
Elaprase will be diluted in 0.9% (9 mg/mL) Sodium Chloride for Injection before use. After dilution Elaprase is given directly
into the vein (intravenously). The infusion will normally last for 1 to 3 hours and will be given every week.
Infusion with Elaprase should start as soon as possible after the medicine has been diluted. If not used immediately, the
solution must be stored at 2°C - 8°C and infused within 24 hours. It should be protected from light before it is given to
you or your child.
If you are given too much (overdose)
There have been no reported overdoses of Elaprase.
Your doctor is trained to work out the correct dose and to contact the Australian Poisons Information Centre (telephone 13
11 26), or the New Zealand National Poisons
Centre (telephone 0800 POISON or 0800 764 766) in case of an overdose.
After having Elaprase
Things you or your child must do
Keep appointments with your doctor or clinic.
It is important to have the infusion with Elaprase at the appropriate times to make sure the medicine has the best chance
of providing treatment for the condition.
Have any tests when your doctor says to.
Your doctor may wish to test your or your child’s body’s response to Elaprase to make sure that it is working.
Your doctor may wish to test for allergic reactions some time after the infusion or continue to monitor after infusion.
Things to be careful of
Allergic reactions may occur approximately 24 hours after infusion.
Tell your health care professional immediately if you experience any allergic reactions.
Be careful driving or operating machinery until you know how Elaprase affects you.
The effect of Elaprase on your ability to drive a car or operate machinery has not been studied.
Make sure that you know how you react to Elaprase before you drive a car or operate machinery or do anything else that may
be dangerous if you are dizzy, light-headed, tired or drowsy.
Tell your doctor or nurse as soon as possible if you or your child do not feel well after having Elaprase.
All medicines can have side effects. Sometimes they are serious, most of the time they are not. You or your child may need
medical treatment if you get some of the side effects. Side effects can happen even if you or your child have been receiving
treatment with Elaprase for some time.
Ask your doctor or nurse to answer any questions you may have.
Tell your doctor or nurse if you notice any of the following and they worry you:
Faintness or dizziness
Redness of skin
If you notice any of the following side effects tell your treating doctor immediately or go to Emergency at your nearest hospital:
Shortness of breath
Inflammation of the back of the throat
Joint pain or swelling itching with or without a rash
Local reaction around the injection site such as swelling
An uncomfortable feeling in the stomach or indigestion
Fever or high temperature
Loss of consciousness
Low blood pressure
Other side effects not listed above may occur in some patients. Tell your doctor if you notice anything making you feel unwell
when you are taking, or soon after you have finished taking Elaprase.
Store Elaprase in a refrigerator at 2°C - 8°C. Do not freeze or shake.
Diluted Elaprase should be protected from light.
If not used immediately, the solution must be stored at 2°C - 8°C and infused within 24 hours.
What it looks like
Elaprase is a clear to slightly opalescent, colourless solution.
sodium chloride, sodium phosphate - monobasic monohydrate, dibasic sodium phosphate heptahydrate, polysorbate 20.
In Australia this product is registered by:
Genzyme Australasia Pty Ltd.
12-24 Talavera Road
Macquarie Park NSW 2113
Toll Free Number (medical information): 1800 818 806
AUST R 129481
In New Zealand this product is registered by:
Sanofi-aventis New Zealand Limited
56 Cawley Street, Ellerslie,
New Zealand Free Call: 0800 283 684
Elaprase® is a registered trademark of Shire Human Genetic Therapies, Inc., USA.
This leaflet was prepared in October 2016